观察多份人脐血单个核细胞（MNC）静脉输注对缺血性脑卒中患者神经功能的改善作用。

选择2008年4月至2015年5月在郑州市第二人民医院、郑州大桥医院住院和门诊收治的缺血性脑卒中患者76例（参照第四届全国脑血管病学术会议修订的脑卒中诊断标准，并经CT、MRI确诊），按照治疗方案的不同分为脐血MNC组和对照组，急性期对照组采用常规治疗，慢性期对照组采用康复治疗，脐血MNC组在常规治疗或康复治疗的基础上加用脐血MNC手背浅静脉输入，每例输入6次，每次细胞数大于或等于1×10⁸个，每次间隔1?~?7?d。治疗前后神经功能缺损程度（NFD）、患侧肢体运动功能评价Fugl-Meyer（FMA）及日常生活评价（ADL）的比较采用配对t检验，组间比较采用独立t检验。

脐血MNC组急性期治疗后NFD评分（11.50 ± 2.58）明显低于急性期脐血MNC组治疗前（26.83 ± 5.55，t?= 6.186，P < 0.01）和对照组治疗后（24.33 ± 5.16，t = 5.442，P < 0.01），脐血MNC组慢性期治疗后NFD评分（12.41?± 3.83）明显低于慢性期脐血MNC组治疗前（23.10± 4.54，t = 10.184，P = 0.000）和对照组治疗后（23.09 ± 3.94，t = 11.012，P < 0.01）；脐血MNC组急性期治疗后Fuel-Meyer（上肢22.16 ± 2.63，下肢32.00 ± 5.32）明显低于急性期脐血MNC组治疗前（上肢11.66?±?2.94，t?=?-6.505，P < 0.01；下肢12.66 ± 3.01，t = -7.5386，P < 0.01）和对照组治疗后（上肢15.00± 3.63，t = -3.871，P = 0.003；下肢16.83 ± 4.91，t = -5.048，P < 0.01），脐血MNC组慢性期治疗后Fuel-Meyer（上肢15.10 ± 2.08，下肢15.03 ± 1.86）明显低于慢性期脐血MNC组治疗前（上肢8.81?±?2.19，t = -11.748，P < 0.01；下肢8.84 ± 2.30，t = -12.619，P < 0.01）和对照组治疗后（上肢9.16 ± 2.60，t = -10.069，P < 0.01；下肢9.69 ± 2.98，t = -11.441，P < 0.01）；脐血MNC组急性期治疗后Barthel指数评分（65.83 ± 7.35）明显低于急性期脐血MNC组治疗前（21.66 ± 5.57，t = -11.916，P < 0.01）和对照组治疗后（42.50± 5.20，t = -6.387，P < 0.01），脐血MNC组慢性期治疗后Barthel指数评分（63.40 ± 9.19）明显低于慢性期脐血MNC组治疗前（25.20±?3.81，t = -21.733，P < 0.01）和对照组治疗后（29.90±5.36，t = 20.361，P < 0.01）。

多份人脐血MNC手背浅静脉移植，方法简便、安全有效，有望成为治疗缺血性脑卒中的有效手段。

To study the effect of multiple human umbilical cord blood mononuclear cells (HCMNC) on the neurological and motor function as well as living activities in patients with ischemic stroke via intravenous transplantation.

According with the Fourth National Conference on cerebrovascular disease, 76 cases of ischemic stroke patients confirmed by CT and MRI, and in the second people's Hospital of Zhengzhou, Zhengzhou bridge hospital and outpatient from April 2008 to May 2015 were collected and divided into treatment group and controls according to the clinical trial protocol. The control groups in the acute and chronic stage were treated routinely and treated with rehabilitation therapy, respectively. On the basis of conventional therapy or rehabilitation therapy, the treatment group was treated with HCMNC of umbilical cord blood which were intravenously infused into the superficial vein of the back of the hand. Each patient received averagely 6 copies (cell number over 1×10⁸/each), each time interval lasted 1 to 7 days, average 4 days. The comparison for the difference of the NFD, FMA and ADL before and after therapy was performed using pared t test and the comparison between groups was made using independent-samples t test.

In acute stage, the NFD scores in HCMNC group after treatment with HCMNC (12.41±3.83) were significantly lower than those in before treatment group (26.83±5.55, t?= 6.186, P?< 0.01) and control group (24.33±5.16, t = 5.442, P < 0.01); In restoration stage, the NFD scores in HCMNC group after treatment with HCMNC (12.41±3.83) were significantly lower than those in before treatment group (23.1±4.54, t = 10.184, P < 0.01) and control group (23.09?±?3.94, t = 11.012, P < 0.01); In acute stage, Fuel-Meyer in HCMNC group after treatment with HCMNC (upper limbs 22.16±2.63, lower limbs 32±5.32) were significantly lower than those in before treatment group (upper limbs 11.66±2.94, t = -6.505, P < 0.01; lower limbs 12.66±3.01, t = -7.5386, P < 0.01) and control group (upper limbs 15±3.63, t = -3.871, P = 0.003; lower limbs 16.83±4.91, t = -5.048, P < 0.01), In restoration stage, Fuel-Meyer in HCMNC group after treatment with HCMNC (upper limbs 15.10±2.08, lower limbs 15.03±1.86) were significantly lower than those in before treatment group (upper limbs 8.81±2.19, t = -11.748, P < 0.01; lower limbs 8.84±2.30, t = -12.619, P < 0.01) and control group (upper limbs 9.16±2.60, t = -10.069, P < 0.01; lower limbs 9.69±2.98, t = -11.441, P < 0.01); In acute stage, Barthel index scores in HCMNC group after treatment with HCMNC (12.41±3.83) were significantly lower than those in before treatment group (21.66±5.57, t?= -11.916, P < 0.01) and control group (42.5±5.2, t = -6.387, P < 0.01); In restoration stage, Barthel index scores in HCMNC group after treatment with HCMNC (63.4±9.19) were significantly lower than those in before treatment group (25.2±3.81, t = -21.733, P < 0.01) and control group (29.9±5.36, t = 20.361, P < 0.01).

The intravenous transplantation of multiple human umbilical cord blood mononuclear cells has been proved a suitable method for the treatment of ischemic stroke with advantages of simpleness, safety and effectivity.